Mitigating Risks from Human Xylazine Exposure - MEETING SUMMARY FEBRUARY 2024 (2)
Mitigating Risks from Human Xylazine Exposure - MEETING SUMMARY FEBRUARY 2024
The Reagan-Udall Foundation for the FDA, in partnership with the U S Food and Drug Administration (FDA), held a hybrid public meeting titled “Mitigating Risks from Human Xylazine Exposure ” This hybrid public meeting explored real-world experiences and scientific evidence on emerging data trends for human xylazine exposure The meeting also examined concrete strategies for drug development and clinical research that directly support the mitigation and reduction of risks associated with human exposure to xylazine Workshop presenters and attendees included clinical and scientific experts, community and harm reduction organizations, persons with lived experience, academic researchers, and federal partners (REAGAN-UDALL FOUNDATION FOR THE FDA, USA, 2024)
https://reaganudall.org/sites/default/files/2024-03/Mitigating%20MMitigating%20Risks%20Xylazine_final.pdf